Akari Therapeutics Plc (AKTX) Financial Statements (2024 and earlier)
Company Profile
Business Address |
24 WEST 40TH STREET NEW YORK, NY 10018 |
State of Incorp. | |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
3/31/2016 Q1 | 12/31/2015 Q4 | 9/30/2015 Q3 | 6/30/2015 Q2 | 3/31/2015 Q1 | 12/31/2014 Q4 | |||
---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
Current Assets | ||||||||
Cash, cash equivalents, and short-term investments | 68,919,995 | 78,772,888 | 2,718,000 | 4,016,000 | ||||
Cash and cash equivalents | 68,919,995 | 78,772,888 | 2,718,000 | 4,016,000 | ||||
Restricted cash and investments | 142,000 | 142,000 | ||||||
Receivables | 10,366 | |||||||
Other undisclosed current assets | 728,126 | 166,141 | 60,000 | 115,000 | ||||
Total current assets: | 69,658,487 | 78,939,029 | 2,920,000 | 4,273,000 | ||||
Noncurrent Assets | ||||||||
Property, plant and equipment | 40,513 | 34,932 | 40,000 | 44,000 | ||||
Intangible assets, net (including goodwill) | 52,483 | 19,341,379 | ||||||
Goodwill | 19,283,280 | |||||||
Intangible assets, net (excluding goodwill) | 52,483 | 58,099 | ||||||
Restricted cash and investments | 142,079 | |||||||
Other undisclosed noncurrent assets | (19,141,201) | |||||||
Total noncurrent assets: | 235,075 | 235,110 | 40,000 | 44,000 | ||||
TOTAL ASSETS: | 69,893,562 | 79,174,139 | 2,960,000 | 4,317,000 | ||||
LIABILITIES AND EQUITY | ||||||||
Liabilities | ||||||||
Current Liabilities | ||||||||
Accounts payable and accrued liabilities | 4,728,810 | 7,599,446 | 960,000 | 910,000 | ||||
Accounts payable | 4,320,588 | 3,753,518 | 960,000 | 910,000 | ||||
Accrued liabilities | 408,222 | 3,845,928 | ||||||
Due to related parties | 3,031,304 | |||||||
Other undisclosed current liabilities | 16,396,158 | 27,165,905 | ||||||
Total current liabilities: | 21,124,968 | 37,796,655 | 960,000 | 910,000 | ||||
Noncurrent Liabilities | ||||||||
Liabilities, other than long-term debt | 43,000 | 38,000 | ||||||
Other liabilities | 43,000 | 38,000 | ||||||
Other undisclosed noncurrent liabilities | 49,069 | 46,038 | 984,000 | 774,000 | ||||
Total noncurrent liabilities: | 49,069 | 46,038 | 1,027,000 | 812,000 | ||||
Total liabilities: | 21,174,037 | 37,842,693 | 1,987,000 | 1,722,000 | ||||
Equity | ||||||||
Equity, attributable to parent | 48,719,525 | 41,331,446 | 973,000 | 2,595,000 | ||||
Common stock | 18,340,894 | 18,340,894 | 927,000 | 927,000 | ||||
Additional paid in capital | 87,018,764 | 86,062,364 | 34,224,000 | 34,175,000 | ||||
Accumulated other comprehensive income (loss) | 156,480 | 197,091 | ||||||
Accumulated deficit | (56,796,613) | (63,268,903) | (34,178,000) | (32,507,000) | ||||
Total equity: | 48,719,525 | 41,331,446 | 973,000 | 2,595,000 | ||||
TOTAL LIABILITIES AND EQUITY: | 69,893,562 | 79,174,139 | 2,960,000 | 4,317,000 |
Income Statement (P&L) (USD)Annual | Quarterly
3/31/2016 Q1 | 12/31/2015 Q4 | 9/30/2015 Q3 | 6/30/2015 Q2 | 3/31/2015 Q1 | 12/31/2014 Q4 | ||
---|---|---|---|---|---|---|---|
Gross profit: | 22,973,138 | (22,973,138) | |||||
Operating expenses | (4,290,950) | (23,326,979) | (1,456,000) | (2,342,000) | |||
Other undisclosed operating income (loss) | (22,973,138) | 22,973,138 | |||||
Operating loss: | (4,290,950) | (23,326,979) | (1,456,000) | (2,342,000) | |||
Nonoperating income (expense) | 10,763,240 | (25,408,711) | (215,000) | (535,000) | |||
Gain (loss), foreign currency transaction, before tax | (30,007) | (22) | |||||
Other nonoperating expense | (215,000) | (535,000) | |||||
Interest and debt expense | 5,950 | (3,054,262) | |||||
Income (loss) from continuing operations before equity method investments, income taxes: | 6,478,240 | (51,789,952) | (1,671,000) | (2,877,000) | |||
Other undisclosed income (loss) from continuing operations before income taxes | (5,950) | 3,054,262 | |||||
Income (loss) from continuing operations before income taxes: | 6,472,290 | (48,735,690) | (1,671,000) | (2,877,000) | |||
Income tax benefit | 560,000 | ||||||
Income (loss) from continuing operations: | 6,472,290 | (48,735,690) | (1,671,000) | (2,317,000) | |||
Income (loss) before gain (loss) on sale of properties: | 6,472,290 | (48,735,690) | (1,671,000) | (2,317,000) | |||
Net income (loss) available to common stockholders, diluted: | 6,472,290 | (48,735,690) | (1,671,000) | (2,317,000) |
Comprehensive Income (USD)Annual | Quarterly
3/31/2016 Q1 | 12/31/2015 Q4 | 9/30/2015 Q3 | 6/30/2015 Q2 | 3/31/2015 Q1 | 12/31/2014 Q4 | ||
---|---|---|---|---|---|---|---|
Net income (loss): | 6,472,290 | (48,735,690) | (1,671,000) | (2,317,000) | |||
Other comprehensive loss | (1,671,000) | ||||||
Comprehensive income (loss): | 6,472,290 | (48,735,690) | (3,342,000) | (2,317,000) | |||
Other undisclosed comprehensive loss, net of tax, attributable to parent | (40,611) | (43,262) | |||||
Comprehensive income (loss), net of tax, attributable to parent: | 6,431,679 | (48,778,952) | (3,342,000) | (2,317,000) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.